Non-invasive prenatal testing for aneuploidy: current status and future prospects

Non-invasive prenatal testing (NIPT) for aneuploidy using cell-free DNA in maternal plasma is revolutionizing prenatal screening and diagnosis. We review NIPT in the context of established screening and invasive technologies, the range of cytogenetic abnormalities detectable, cost, counseling and ethical issues. Current NIPT approaches involve whole-genome sequencing, targeted sequencing and assessment of single nucleotide polymorphism (SNP) differences between mother and fetus. Clinical trials have demonstrated the efficacy of NIPT for Down and Edwards syndromes, and possibly Patau syndrome, in high-risk women. Universal NIPT is not cost-effective, but using NIPT contingently in women found at moderate or high risk by conventional screening is cost-effective. Positive NIPT results must be confirmed using invasive techniques. Established screening, fetal ultrasound and invasive procedures with microarray testing allow the detection of a broad range of additional abnormalities not yet detectable by NIPT. NIPT approaches that take advantage of SNP information potentially allow the identification of parent of origin for imbalances, triploidy, uniparental disomy and consanguinity, and separate evaluation of dizygotic twins. Fetal fraction enrichment, improved sequencing and selected analysis of the most informative sequences should result in tests for additional chromosomal abnormalities. Providing adequate prenatal counseling poses a substantial challenge given the broad range of prenatal testing options now available.

Use of the genetic sonogram in the United States in 2001 and 2007

OBJECTIVE

The purpose of this study was to determine whether there have been changes in the use of second-trimester genetic sonograms and in the second-trimester sonographic markers used to screen for fetal aneuploidy by maternal-fetal medicine specialists in the United States from 2001 to 2007.

METHODS

A survey was mailed to Society for Maternal-Fetal Medicine members in the United States in April 2007 inquiring about their practice patterns regarding the genetic sonogram. Specific sonographic markers used for risk adjustment as part of the genetic sonogram were also assessed. The responses from 2007 were compared with responses from a similar survey administered in 2001 (Am J Obstet Gynecol 2002; 187:1230-1234) using descriptive statistics, the chi(2) test, and the Wilcoxon rank sum test.

RESULTS

A total of 991 responses were analyzed: 543 of 1638 (32%) in 2001 and 448 of 1756 (26%) in 2007. Significant increases (P < .0001) were noted in the number of specialists who used the genetic sonogram as a screening tool for Down syndrome and for every single sonographic marker used to adjust a woman's risk for having a fetus with Down syndrome during a genetic sonogram, except for choroid plexus cyst, clinodactyly, sandal gap toes, and widened pelvic angle.

CONCLUSIONS

Practitioners in the United States are using an increasing number of second-trimester sonographic markers to help identify aneuploid fetuses. The growing acceptance of sonography to screen for fetal aneuploidy and the recommendation by the American College of Obstetricians and Gynecologists for universal screening suggest that more resources may be necessary to meet the growing demand for second-trimester sonograms.

Neue Möglichkeiten in der pränatalen Diagnostik

Mit den technischen Entwicklungen erweiterten sich in den letzten Jahren die Einsatzmöglichkeiten des pränatalen Ultraschalls. So konnten in den 80er und 90er-Jahren zunehmend fetale Fehlbildungen diagnostiziert und spezifiziert werden. Die Untersuchung mit der sonographischen Nackentransparenzmessung in der 11. bis 14. Schwangerschaftswoche findet nunmehr als wichtiges pränatales Screening zur individuellen Risikoabschätzung für Chromosomenstörungen Eingang in die pränatale Medizin. Neben der standardisierten Untersuchungstechnik sollte größter Wert auf die ausführliche Information und Beratung der Schwangeren sowie auf die Qualitätssicherung gelegt werden. Durch die Verbesserung der individuellen Risikospezifizierung mittels Sonographie, biochemischen Markern und dem mütterlichen Alter können unnötige invasive Untersuchungen vermieden und ihre Zahl insgesamt deutlich reduziert werden. Ein Trend, der sich auch anhand des nicht-invasiven Nachweises des fetalen Rhesus D Status und mit dem Einsatz der Dopplersonographie im Management fetaler Anämien verfolgen lässt.